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Feasibility of idiotype vaccination in relapsed
B-cell malignancies
Feasibility of idiotype vaccination was statistically com-
pared among five different B-cell malignancies in first
relapse. When based on hybridoma production techniques,
idiotypic vaccination for relapsed B-cell malignancies was
consistently feasible only in follicular lymphoma patients,
whereas the main cause of failure in other settings was the
short survival of idiotype-producing hybridomas.haematologica 2003; 88:1438-1440
(http://www.haematologica.org/2003_12/1438.htm)
With two ongoing, phase-III clinical trials enrolling newly-
diagnosed follicular lymphoma (FL) patients, idiotypic vaccina-
tion1 is approaching the final stage of its clinical development,
that of demonstrating a possible benefit to patients. However,
even in the event that either or both ongoing clinical trials suc-
ceed, a number of relevant questions would still remain unan-
swered, in particular whether idiotype (Id) vaccines may be fea-
sible for most if not all relapsed FL and for some other B-cell
malignancies.
An interim analysis was performed of all Id vaccine clinical
trials currently ongoing at our institution based on a single,
major endpoint, that is actual ability to administer an Id vac-
cine according to intention-to-treat. Inclusion criteria common
to all cases were that the Id vaccine production attempt was
carried out only at the time of pathologically-confirmed first
relapse and that there was a prior, formal demonstration of the
presence of a complete, clonal and tumor-specific immunoglob-
ulin on the tumor cell surface. Furthermore, all Id vaccine pro-
duction attempts were carried out by the same personnel and
always using the same fusion partner (K6H6/B5, i.e. ATCC num-
ber: CRL-1823), according to the standard tumor/hetero-
hybridoma fusion-based method previously described.2-5 All
patients received the chemotherapy regimen currently in use at
our institution for their respective disease in first relapse (Table
1). Patients with FL, mantle cell lymphoma and small lympho-
cytic lymphoma were supposed to receive Id vaccine treatment
if they achieved either complete (CR) or partial (PR) response,
while patients with either diffuse large cell or Burkitt’s lym-
phoma were supposed to receive Id vaccine treatment only if
they achieved a CR.
Id vaccine treatment unfeasibility was evaluated as (i) relat-
ed to induction treatment, if the salvage therapy did not induce
a response sufficient to proceed with Id vaccination, (ii) fusion-
related, if sufficient Id could not be generated to make the vac-
cine, or (iii)  overall. Fusion-related feasibility was evaluated by
taking into consideration both its potential causes of failure:
short hybridoma survival and loss of Id production.
The feasibility of Id vaccination in relation to induction treat-
ment was markedly different, being 80%-100% in indolent NHL
subtypes and 40%-50% in aggressive ones. This difference was
not, however, due to an overall lack of efficacy of the respec-
tive chemotherapy regimens, but rather to the different eligi-
bility criteria for Id vaccination following chemotherapy. In fact,
the overall response to induction treatment for aggressive NHL
was 75%-80% (CR+PR), but in this group only patients achiev-
ing CR were considered eligible to receive Id vaccination. A far
more important factor that halted treatment was Id-secreting
hybridoma production (Table 2). Fusion experiments were suc-
cessful in most FL cases at the very first attempt, whereas in
other NHL cases, irrespective of the ultimate Id production out-
come, as many as 5 attempts had to be carried out most of the
time. Similarly, in most FL cases, the average number of suc-
cessful fusion wells per 96-well plate was well above 15, where-
as that of most of the other NHL cases was typically lower than
five.
Statistically significant differences in fusion-related and
overall feasibility were found between cases of FL and those of
all other NHL, indolent and aggressive lymphoma, respectively
(Table 2). Both fusion-related and overall feasibility of the Id
vaccine treatment for FL in first relapse were comparable with
those already described for both newly-diagnosed and relapsed
patients with the same disease.3-5 Interestingly, the Id vaccine
production success rate was substantially low in cases of man-
tle cell lymphoma (MCL), as opposed to what has been prelim-
inarily described with the very same method in newly-diag-
nosed MCL patients.6 This apparent discrepancy could be due,
at least in theory, to MCL cells at first relapse biologically
resembling those of aggressive NHL rather than FL clones, with
obvious possible repercussions on the fusion process.
Letters to the Editor
1438 haematologica/journal of hematology vol. 88(12):december 2003
Table 1. Induction treatment-related Id vaccine fea-
sibility. 
Diagnosis Number Induction Number Induction
of patients treatment of  CR/PR treatment-
related 
feasibility
FL 15 CHOP×6 9/5 14/15 
(93%)
MCL 5 R-HyperCVAD 2/2 4/5 
×8 (80%)
SLL 5 FMC×6 4/1 5/5 
(100%)
DLCL 5 mini BEAM×3 2/2 2/5 
+ BEAM + ABMT (40%)
BL 4 mini BEAM×3 2/1 2/4 
+ BEAM + ABMT (50%)
All but FL 19 See above 10/3 + 3 13/19 
(68%)
MCL+SLL 10 See above 6/3 9/10 
(90%)
DLCL+BL 9 See above 4/3 4/9
(44%)
Underlined CR and PR numbers refer to the cases for which subse-
quent Id vaccination was ethically acceptable according to the
respective clinical trial protocols. 
The main cause for Id vaccine production failure was poor
hybridoma survival (15/18 cases), which accounted for 100% of
failures in aggressive lymphoma (9/9 cases). Loss of Id secretion
by growing hybridomas accounted for only 3/18 cases of Id
vaccine production failure (Table 2).
All in all, our data suggest that, in the vast majority of cas-
es, the feasibility of idiotypic vaccination for patients with first-
relapse B-cell malignancies strictly depends on the ultimate
ability to produe a viable Id vaccine rather than on the proba-
bility of inducing a clinical response suitable for subsequent
idiotypic vaccination. In this respect, first-relapse FL clearly
appears more suitable for hybridoma-based Id vaccine produc-
tion than any other first-relapse NHL subtype tested in our lab-
oratory.
As a major consequence of these data, clinical trials on Id
vaccination for B-cell lymphomas other than FL in first relapse
have been closed. However, it is possible that alternative meth-
ods to produce the Id protein, particularly those based on mol-
ecular techniques,7-10 may prove far more efficient than the tra-
ditional approach we used in this study.
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Table 2. Fusion-related and overall Id vaccine feasibility.
Diagnosis No. of Fusion attempts 96-well plates Successful fusion wells Fusion-related Cause of Overall
patients median (range) median (range) median (range) feasibility fusion failure feasibility
(SHS/LIP)
FL 15 1 (1-5) 10 ( 8-12) 186 (63-238) 13/15 (87%)* 1/1 13/15 (87%)*
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MCL+SLL 10 5 (2-5) 15 (10-15) 65 (27-102) 3/10 (30%)* 5/2 2/10 (20%)*
DLCL+BL 9 5 15 (10-15) 51 (29-80) 0/9 (0%)* 9/0 0/9 (0%)*
Fisher’s exact test with Bonferroni’s correction was used to compare both the likelihood of a successful fusion and the overall feasibility of the
treatment among patients with either FL or the remaining subtypes of both indolent and aggressive lymphoma. The level of significance
required after this post-hoc correction was 0.025 (exact 2-tailed P). SHS: Short hybridoma survival. LIP: Loss of Id production. *p < 0.01.
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